Sonrai Analytics, a Belfast-based innovator in Artificial Intelligence (AI) data discovery, and California-based IV BioHoldings (IVBH), a precision health company in liquid biopsy, have announced a strategic partnership to accelerate early detection of diseases with poor clinical outcomes.
The partnership brings Sonrai’s cloud AI technology for discovering, developing, and validating high-value biomarkers to IVBH’s commercial portfolio: LiquidLung, HepGene and Mammogen. The collaboration aims to streamline the ability to identify, validate and productise novel biomarkers for the effective early detection and subsequent actionable treatment of patients with progressive disease.
IVBH is a clinical-stage bio-platform company that conceives, creates, and scales first-generation precision health solutions that improve the detection, diagnosis, and treatment of disease. They have made commendable strides across multiple disease and cancer areas and have chosen to collaborate with Sonrai to help drive their ambitious clinical pipelines.
The collaboration will entail Sonrai’s development of novel algorithms applied to specific disease areas to solidify and validate signatures supporting IVBH’s expertise and clinical pipeline. It will empower the creation of eight best-in-class diagnostics for patients. IVBH’s goal is to radically transform the diagnostic sector, with the first clinical data readout expected for the genTRU breast cancer detection program this summer. This will be followed closely by the lung cancer and NAFLD programs, with plans for reaching a commercial launch phase for all three programs by the end of 2023 and an eye toward future expansion across the IVBH offering.
RELATED: Clarius partners with ImaCor on handheld hemodynamic ultrasound tech
Sonrai founder and CEO Dr Darragh McArt, said: “We are delighted to partner with IVBH as our key goals in driving discovery and transforming healthcare are aligned. These goals aligned perfectly not just with the experience of the Sonrai team but also with the intentional design of Sonrai’s decentralised and highly flexible AI platform, making this partnership a very natural fit.”
IVBH Founder and CEO Marty Keiser added: “Digital analytics within precision medicine requires many facets today to discover and validate markers that will optimally define patient groups to receive the right treatment. As a data-driven, technology-led organisation, it’s critical that we’re maximising our utilisation of advanced analytical science and exponential technologies, such as those developed by Sonrai’s world-class team of data scientists and engineers.”
IVBH senior vice president and CCO Elizabeth Cormier-May commented: “The collaboration with Sonrai unlocks massive clinical and commercial value across the IVBH platform. With our tests poised to positively impact the lives of millions of people globally, Sonrai’s engine helps us to unlock early disease detection across three of the largest clinical markets.”
The partnership announcement comes after Sonrai had raised £2.175 million in Seed Plus funding to accelerate the adoption of its technology.
